Pfizer’s Champix (varenicline tartrate) 0.5mg and 1mg tablets are currently in short supply following disruption in the manufacturing of the drug.
The shortage of the smoking cessation drug might continue a bit longer, as Pfizer is trying to address the issue.
The company has not given a timeline to resolve the situation.
“We understand and regret the challenges that the situation poses and realise the importance of this medicine to healthcare professionals and patients,” Pfizer said in a statement.
The drug maker also encouraged patients to consult healthcare professionals to find an alternative option of Champix.
“We remain committed to supporting smokers in their quit attempts. However, until the Champix shortage is resolved, patients will need to consult with their healthcare professional to choose an alternative treatment option,” Pfizer added.